Changes in Airway Histone Deacetylase2 in Smokers and COPD with Inhaled Corticosteroids: A Randomized Controlled Trial

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Sohal, Sukhwinder Singh ^a   Reid, David ^a,b   Soltani, Amir ^a   Weston, Steven ^a   Muller, Hans Konrad ^a   Wood Baker, Richard ^a   Walters, Eugene Haydn ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HISTONE DEACETYLASE 2;

ADULT; AGED; ARTICLE; BRONCHOSCOPY; BRONCHUS BIOPSY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; LAMINA PROPRIA; LUNG FUNCTION; LUNG LAVAGE; MALE; RANDOMIZED CONTROLLED TRIAL; SMOKING;

ADMINISTRATION, INHALATION; AGED; BRONCHI; BRONCHOSCOPY; FEMALE; HISTONE DEACETYLASE 2; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 84878026838     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064833     Document Type: Article

References (26)

1. Barnes PJ, (2003) New concepts in chronic obstructive pulmonary disease. Annu Rev Med 54: 113-129.
2. Barnes PJ, Adcock IM, Ito K, (2005) Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 25: 552-563.
3. Reid DW, Wen Y, Johns DP, Williams TJ, Ward C, et al. (2008) Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related. Respirology 13: 799-809.
4. Chanez P, Bourdin A, Vachier I, Godard P, Bousquet J, et al. (2004) Effects of inhaled corticosteroids on pathology in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 1: 184-190.
5. Telenga ED, Kerstjens HA, Postma DS, Ten Hacken NH, van den Berge M, (2010) Inhaled corticosteroids in chronic obstructive pulmonary disease: a review. Expert Opin Pharmacother 11: 405-421.
6. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, et al. (2001) Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 15: 1110-1112.
7. Barnes PJ, (2006) Reduced histone deacetylase in COPD: clinical implications. Chest 129: 151-155.
8. Sohal SS, Reid D, Soltani A, Weston S, Muller HK, et al. (2010) Smoking cessation but not inhaled corticosteroids (ICS) can increase histone deacetylase 2 (HDAC2) in COPD. European Respiratory Journal, Abstract book 36: 785S.
9. Barnes PJ, (2006) Corticosteroid effects on cell signalling. Eur Respir J 27: 413-426.
10. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, et al. (1999) Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 340: 1948-1953.
11. Vestbo J, (2004) The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 24: 206-210.
12. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC, (2002) The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 165: 1592-1596.
13. Gizycki MJ, Hattotuwa KL, Barnes N, Jeffery PK, (2002) Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 57: 799-803.
14. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, et al. (2009) Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 151: 517-527.
15. Zanini A, Chetta A, Saetta M, Baraldo S, Castagnetti C, et al. (2009) Bronchial vascular remodelling in patients with COPD and its relationship with inhaled steroid treatment. Thorax 64: 1019-1024.
16. GOLD (2007) Global Strategy for the Diagnosis, Mangement and Prevention of Chronic Obstructive Pulmonary Disease. Update 2007.
17. Feltis BN, Wignarajah D, Zheng L, Ward C, Reid D, et al. (2006) Increased vascular endothelial growth factor and receptors: relationship to angiogenesis in asthma. Am J Respir Crit Care Med 173: 1201-1207.
18. Richmond I, Booth H, Ward C, Walters EH, (1996) Intrasubject variability in airway inflammation in biopsies in mild to moderate stable asthma. Am J Respir Crit Care Med 153: 899-903.
19. Sohal SS, Reid D, Soltani A, Ward C, Weston S, et al. (2010) Reticular basement membrane fragmentation and potential epithelial mesenchymal transition is exaggerated in the airways of smokers with chronic obstructive pulmonary disease. Respirology 15: 930-938.
20. Sohal SS, Reid D, Soltani A, Ward C, Weston S, et al. (2011) Evaluation of epithelial mesenchymal transition in patients with chronic obstructive pulmonary disease. Respir Res 12: 130.
21. Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle GG, (2006) Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir Res 7: 53.
22. Hodge S, Hodge G, Holmes M, Reynolds PN, (2005) Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J 25: 447-454.
23. Park JW, Ryter SW, Choi AM, (2007) Functional significance of apoptosis in chronic obstructive pulmonary disease. COPD 4: 347-353.
24. Plataki M, Tzortzaki E, Rytila P, Demosthenes M, Koutsopoulos A, et al. (2006) Apoptotic mechanisms in the pathogenesis of COPD. Int J Chron Obstruct Pulmon Dis 1: 161-171.
25. Soltani A, Reid DW, Sohal SS, Wood-Baker R, Weston S, et al. (2010) Basement membrane and vascular remodelling in smokers and chronic obstructive pulmonary disease: a cross-sectional study. Respir Res 11: 105.
26. Glare EM, Divjak M, Bailey MJ, Walters EH, (2002) beta-Actin and GAPDH housekeeping gene expression in asthmatic airways is variable and not suitable for normalising mRNA levels. Thorax 57: 765-770.